Análisis del costo y la efectividad de los esquemas de administración de factores de coagulación para el manejo de niños con hemofilia A en México

Salinas-Escudero, Guillermo; Galindo-Suárez, Rosa María; Rely, Kely; Carrillo-Vega, María Fernanda; Muciño-Ortega, Emilio.
Bol. méd. Hosp. Infant. Méx ; 70(4): 290-298, jul.-ago. 2013. ilus, tab
Artículo en Español | LILACS | ID: lil-702401

Documentos relacionados

  1. Consensus on hemophilia in Mexico.
  2. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
  3. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
  4. Evaluación de profilaxis con factor VIII de origen plasmático en pacientes con hemofilia A severa
  5. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
  6. Acquired hemophilia type A in the intensive care unit. Case reports.
  7. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
  8. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment.
  9. Acquired hemophilia.
  10. Prophylactic Treatment of Children with Hemophilia in Sweden.